Product/Composition:- | Iloprost inahalation Solution |
---|---|
Strength:- | 10 mcg/mL |
Form:- | Inhalation Solution (Nebulizer) |
Reference Brands:- | Ventavis®(EU & US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Iloprost inhalation solution is a prostacyclin analogue that dilates pulmonary blood vessels, reducing pulmonary arterial pressure. It inhibits platelet aggregation, preventing clots. Benefits include improved exercise capacity, symptom relief, and enhanced quality of life for PAH patients, especially in those with advanced disease requiring targeted inhalation therapy.
Iloprost inhalation solution, marketed as Ventavis®, is approved in the US and EU for pulmonary arterial hypertension (PAH). Regulatory dossiers include detailed clinical trials, manufacturing standards, and safety data submitted to FDA and EMA, supporting its approval. The inhalation therapy delivers prostacyclin directly to the lungs, improving exercise capacity and symptoms. The product is supplied in vials of 20 mcg/mL for nebulization, with dosing tailored to individual patient needs. For comprehensive insights on regulatory submissions, dossier requirements, and market approvals, visit PharmaTradz, your trusted source for pharmaceutical regulatory updates and industry insights.